(Q35557450)

8 August 2017

1 reference

title

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? (English)

1 reference

8 August 2017

4

Alessandro Morabito

1 reference

8 August 2017

Giampietro Gasparini

1

1 reference

PubMed ID

14554238

8 August 2017

Raffaele Longo

series ordinal

2

1 reference

PubMed ID

14554238

8 August 2017

Roberta Sarmiento

series ordinal

3

1 reference

8 August 2017

1 October 2003

1 reference

Lancet Oncology Commission

8 August 2017

1 reference

8 August 2017

4

1 reference

8 August 2017

605-615

1 reference

8 August 2017

10

1 reference

Celecoxib: a specific COX-2 inhibitor with anticancer properties

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Regulation of cyclooxygenase-2 pathway by HER2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Inducible cyclooxygenase may have anti-inflammatory properties

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Genetic and pharmacological analysis of prostanoid receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Prostanoid receptors: structures, properties, and functions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Is cyclooxygenase-2 the alpha and the omega in cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha aopototic signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Sulindac inhibits activation of the NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Role of BAX in the apoptotic response to anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Warfarin and celecoxib interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Metronomic scheduling: the future of chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Targeting angiogenic processes by combination rofecoxib and ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Combinatorial chemoprevention of intestinal neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901220-8

7 January 2021

10.1016/S1470-2045(03)01220-8

Identifiers

DOI

1 reference

8 August 2017

1 reference

PubMed ID

14554238